Advanced search
Publication Cover
Annals of Medicine Volume 48, 2016 - Issue 5
Submit an article Journal homepage
3,170
Views
100
CrossRef citations to date
0
Altmetric
Original Article

Liver fat accumulation is associated with circulating PCSK9

Massimiliano RuscicaDepartment of Pharmacological and Biomolecular Sciences, Università Degli Studi Di Milano, Milano, Italy;
,
Nicola FerriDepartment of Pharmaceutical and Pharmacological Sciences, Università di Padova, Padova, Italy;
,
Chiara MacchiDepartment of Pharmacological and Biomolecular Sciences, Università Degli Studi Di Milano, Milano, Italy;
,
Marica MeroniDepartment of Pathophysiology and Transplantation, Università Degli Studi Di Milano, Milano, Italy;
,
Claudia LantiInternal Medicine and Metabolic Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy;
,
Chiara RicciDepartment of Pharmacological and Biomolecular Sciences, Università Degli Studi Di Milano, Milano, Italy;
,
Marco MaggioniDepartment of Pathology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy;
,
Anna Ludovica FracanzaniDepartment of Pathophysiology and Transplantation, Università Degli Studi Di Milano, Milano, Italy; ;Internal Medicine and Metabolic Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy;
,
Sara BadialiDepartment of Surgery, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy
,
Silvia FargionDepartment of Pathophysiology and Transplantation, Università Degli Studi Di Milano, Milano, Italy; ;Internal Medicine and Metabolic Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy;
,
Paolo MagniDepartment of Pharmacological and Biomolecular Sciences, Università Degli Studi Di Milano, Milano, Italy;
,
Luca ValentiDepartment of Pathophysiology and Transplantation, Università Degli Studi Di Milano, Milano, Italy; ;Internal Medicine and Metabolic Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; Correspondence[email protected]
&
Paola DongiovanniInternal Medicine and Metabolic Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy;
show all
Pages 384-391 | Received 05 Feb 2016, Accepted 06 May 2016, Published online: 25 May 2016

Citations (100)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Amir Abbas Momtazi-Borojeni, Maciej Banach, Massimiliano Ruscica & Amirhossein Sahebkar. (2022) The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition. Expert Review of Clinical Pharmacology 15:10, pages 1199-1208.
Read now
M. Ruscica, N. Ferri, C. Macchi, A. Corsini & C. R. Sirtori. (2018) Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. Annals of Medicine 50:6, pages 461-484.
Read now
Konstantinos P. Imprialos, Konstantinos Stavropoulos, Michael Doumas, Anastasia Skalkou, Ioanna Zografou & Vasilios G. Athyros. (2018) The potential role of statins in treating liver disease. Expert Review of Gastroenterology & Hepatology 12:4, pages 331-339.
Read now
Maria Pia Adorni, Nicola Ferri, Silvia Marchianò, Valentina Trimarco, Francesco Rozza, Raffaele Izzo, Franco Bernini & Francesca Zimetti. (2017) Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9. Therapeutics and Clinical Risk Management 13, pages 1555-1562.
Read now

Articles from other publishers (96)

Omid Alavi, Maryam Hozhabri, Farshad Sheikhesmaili, Mohammad Moradzad, Rezgar Rahbari, Nariman Moradi & Zakaria Vahabzadeh. (2023) PCSK9 polymorphism rs505151 is associated with the risk of NAFLD in Iranian participants: A case-control study. Gene Reports, pages 101864.
Crossref
Liuxin Ning, Yanting Zou, Shuyu Li, Yue Cao, Beili Xu, Shuncai Zhang & Yu Cai. (2023) Anti-PCSK9 Treatment Attenuates Liver Fibrosis via Inhibiting Hypoxia-Induced Autophagy in Hepatocytes. Inflammation 46:6, pages 2102-2119.
Crossref
Federico Bigazzi, Carlotta Francesca De Pasquale, Sandra Maestro, Carmen Corciulo, Beatrice Dal Pino, Francesco Sbrana & Tiziana Sampietro. (2023) PCSK9 and leptin plasma levels in anorexia nervosa. Hormones.
Crossref
Jiaming Li, Muzhao Xiong, Xiang-Hong Fu, Yanling Fan, Chen Dong, Xiaoyan Sun, Fang Zheng, Si-Wei Wang, Lixiao Liu, Ming Xu, Cui Wang, Jiale Ping, Shanshan Che, Qiaoran Wang, Kuan Yang, Yuesheng Zuo, Xiaoyong Lu, Zikai Zheng, Tian Lan, Si Wang, Shuai Ma, Shuhui Sun, Bin Zhang, Chen-Shui Chen, Ke-Yun Cheng, Jinlin Ye, Jing Qu, Yongbiao Xue, Yun-Gui Yang, Feng Zhang, Weiqi Zhang & Guang-Hui Liu. (2023) Determining a multimodal aging clock in a cohort of Chinese women. Med 4:11, pages 825-848.e13.
Crossref
Csaba Matyas, Eszter Trojnar, Suxian Zhao, Muhammad Arif, Partha Mukhopadhyay, Attila Kovacs, Alexandra Fabian, Marton Tokodi, Zsolt Bagyura, Bela Merkely, Laszlo Kohidai, Eszter Lajko, Angela Takacs, Yong He, Bin Gao, Janos Paloczi, Falk W. Lohoff, György Haskó, Wen-Xing Ding & Pal Pacher. (2023) PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction. JACC: Basic to Translational Science 8:10, pages 1334-1353.
Crossref
Julia Brandts & Kausik K. Ray. (2023) Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. Nature Reviews Cardiology 20:9, pages 600-616.
Crossref
Xiaomeng Cui, Menglin Yao, Yanjing Feng, Chengjun Li, Yarui Li, Dan Guo & Shuixiang He. (2023) Exogenous hydrogen sulfide alleviates hepatic endoplasmic reticulum stress via SIRT1 / FoxO1 / PCSK9 pathway in NAFLD . The FASEB Journal 37:8.
Crossref
Andrew S. Bell, Josephin Wagner, Daniel B. Rosoff & Falk W. Lohoff. (2023) Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system. Neuroscience & Biobehavioral Reviews 149, pages 105155.
Crossref
Khrystyna Platko, Paul F. Lebeau, Joshua P. Nederveen, Jae Hyun Byun, Melissa E. MacDonald, Jacqueline M. Bourgeois, Mark A. Tarnopolsky & Richard C. Austin. (2023) A Metabolic Enhancer Protects against Diet-Induced Obesity and Liver Steatosis and Corrects a Pro-Atherogenic Serum Profile in Mice. Nutrients 15:10, pages 2410.
Crossref
Dan Wang & Daqing Zhang. (2022) Safety Issues Associated With the Clinical Application of PCSK9 Inhibitors: Current Findings. Cardiology in Review 31:3, pages 155-161.
Crossref
Yi Jing, Tianhui Hu, Jun Yuan, Zhikun Liu, Mingtao Tao, Mingyu Ou, Xinru Cheng, Wei Cheng, Yuanyuan Yi & Qingping Xiong. (2023) Resveratrol protects against postmenopausal atherosclerosis progression through reducing PCSK9 expression via the regulation of the ERα-mediated signaling pathway. Biochemical Pharmacology 211, pages 115541.
Crossref
Melissa Tomasi, Alessandro Cherubini, Serena Pelusi, Sara Margarita, Cristiana Bianco, Francesco Malvestiti, Lorenzo Miano, Stefano Romeo, Daniele Prati & Luca Valenti. (2023) Circulating Interlukin-32 and Altered Blood Pressure Control in Individuals with Metabolic Dysfunction. International Journal of Molecular Sciences 24:8, pages 7465.
Crossref
Krisztina Németh, Blanka Tóth, Farkas Sarnyai, Anna Koncz, Dorina Lenzinger, Éva Kereszturi, Tamás Visnovitz, Brachyahu Meir Kestecher, Xabier Osteikoetxea, Miklós Csala, Edit I. Buzás & Viola Tamási. (2023) High fat diet and PCSK9 knockout modulates lipid profile of the liver and changes the expression of lipid homeostasis related genes. Nutrition & Metabolism 20:1.
Crossref
Ehsan Amini-Salehi, Soheil Hassanipour, Farahnaz Joukar, Amir Ali Daryagasht, Mohammad-Javad Khosousi, Maryam Sadat Aleali, Malek Moien Ansar, Forough Heidarzad, Elham Abdzadeh, Azin Vakilpour & Fariborz Mansour-Ghanaei. (2023) Risk Factors of Non-alcoholic Fatty Liver Disease in the Iranian Adult Population: A Systematic Review and Meta-analysis. Hepatitis Monthly 23:1.
Crossref
Oluwakemi Ebenezer, Pietro Comoglio, Gane Ka-Shu Wong & Jack A. Tuszynski. (2023) Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia. International Journal of Molecular Sciences 24:4, pages 4019.
Crossref
Amita Singh, Pranesh Kumar, Archana Bharti Sonkar, Anurag Kumar Gautam, Abhishek Verma, Biswanath Maity, Himani Tiwari, Nanda Gopal Sahoo, Amit K. Keshari, S.K. Yadav & Sudipta Saha. (2023) A Comprehensive Review on PCSK9 as Mechanistic Target Approach in Cancer Therapy. Mini-Reviews in Medicinal Chemistry 23:1, pages 24-32.
Crossref
Rosaria Vincenza Giglio, Emir M. Muzurović, Angelo Maria Patti, Peter P. Toth, Manyoo A. Agarwal, Wael Almahmeed, Aleksandra Klisic, Marcello Ciaccio & Manfredi Rizzo. (2023) Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?. Journal of Cardiovascular Pharmacology and Therapeutics 28.
Crossref
Daqing Zhang, Zhen Mi, Jiya Peng, Tiangui Yang, Yuze Han, Yujia Zhai, Chenliang Song, Xianzhuo Teng, Wei Sun, Jing Guo & Kabeya Paulin Bilonda. (2023) Nonalcoholic Fatty Liver Disease as an Emerging Risk Factor and Potential Intervention Target for Atherosclerotic Cardiovascular Diseases. Journal of Cardiovascular Pharmacology 81:5, pages 327-335.
Crossref
Jerome Gilleron & Anja Zeigerer. (2022) Endosomal trafficking in metabolic homeostasis and diseases. Nature Reviews Endocrinology 19:1, pages 28-45.
Crossref
Jia Peng, Ming-Ming Liu, Jing-Lu Jin, Ye-Xuan Cao, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Qian Dong, Jing Sun, Rui-Xia Xu & Jian-Jun Li. (2022) NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study. Lipids in Health and Disease 21:1.
Crossref
Kevan Josloff, Jacob Beiriger, Adnan Khan, Richard J. Gawel, Richard S. Kirby, Aaron D. Kendrick, Abhinav K. Rao, Roy X. Wang, Michelle M. Schafer, Margaret E. Pearce, Kashyap Chauhan, Yash B. Shah, Gregary D. Marhefka & Dina Halegoua-DeMarzio. (2022) Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. Journal of Cardiovascular Development and Disease 9:12, pages 419.
Crossref
Fang Jia, Si-Fan Fei, De-Bing Tong, Cong Xue & Jian-Jun Li. (2022) Sex difference in circulating PCSK9 and its clinical implications. Frontiers in Pharmacology 13.
Crossref
Mengyun Xu, Xiumei Wu, Zhenghong Liu, Yu Ding, Weian Kong, Peter J. Little, Suowen Xu & Jianping Weng. (2022) A novel mouse model of diabetes, atherosclerosis and fatty liver disease using an AAV8-PCSK9-D377Y injection and dietary manipulation in db/db mice. Biochemical and Biophysical Research Communications 622, pages 163-169.
Crossref
Hui-Chun Huang, Shao-Jung Hsu, Ching-Chih Chang, Chiao-Lin Chuang, Ming-Chih Hou & Fa-Yauh Lee. (2022) Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats. International Journal of Molecular Sciences 23:13, pages 7378.
Crossref
Wenqiang Zhu, Chen Ding, Piaopiao Huang, Juanli Ran, Pingan Lian, Yaxin Tang, Wen Dai & Xiansheng Huang. (2022) Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway. Scientific Reports 12:1.
Crossref
George N. Ioannou, Sum P. Lee, Peter S. Linsley, Vivian Gersuk, Matthew M. Yeh, Yen‐Ying Chen, Yi‐Jen Peng, Moumita Dutta, Gabby Mascarinas, Bruk Molla, Julia Yue Cui & Christopher Savard. (2021) Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol. Hepatology Communications 6:4, pages 780-794.
Crossref
Youn Huh, Yoon Jeong Cho & Ga Eun Nam. (2022) Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. Journal of Obesity & Metabolic Syndrome 31:1, pages 17-27.
Crossref
Paul F. Lebeau, Khrystyna Platko, Jae Hyun Byun, Yumna Makda & Richard C. Austin. (2022) The Emerging Roles of Intracellular PCSK9 and Their Implications in Endoplasmic Reticulum Stress and Metabolic Diseases. Metabolites 12:3, pages 215.
Crossref
Zheng-Yu Tao & Jing Zeng. (2022) Role of non-alcoholic fatty liver disease in development of cardiovascular disease. World Chinese Journal of Digestology 30:3, pages 136-139.
Crossref
Huixing Liu & Daoquan Peng. (2022) Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism. Endocrine Connections 11:2.
Crossref
Thomas Grewal & Christa Buechler. (2022) Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond. International Journal of Molecular Sciences 23:3, pages 1070.
Crossref
Noha Adly Sadik, Laila Ahmed Rashed & Shereen Sadik El-Sawy. (2022) The Relationship of Circulating Proprotein Convertase Subtilisin/Kexin Type 9 With TSH and Lipid Profile in Newly Diagnosed Patients With Subclinical and Overt Hypothyroidism. Clinical Medicine Insights: Endocrinology and Diabetes 15, pages 117955142210933.
Crossref
Maria Apostolopoulou & Michael Roden. 2022. Nicht-alkoholische Fettlebererkrankung. Nicht-alkoholische Fettlebererkrankung 211 225 .
Małgorzata Waluś-Miarka, Maria Kapusta, Przemysław Miarka, Ewa Kawalec & Barbara Idzior-Waluś. (2021) Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes. Cardiovascular Therapeutics 2021, pages 1-9.
Crossref
Ahad Eshraghian, Elham Moasser, Negar Azarpira, Mohammad Reza Fattahi, Saman Nikeghbalian, Seyed Ali Malek-Hosseini & Bita Geramizadeh. (2021) Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study. BMC Gastroenterology 21:1.
Crossref
Scott A. Willis, Stephen J. Bawden, Sundus Malaikah, Jack A. Sargeant, David J. Stensel, Guruprasad P. Aithal & James A. King. (2021) The role of hepatic lipid composition in obesity‐related metabolic disease. Liver International 41:12, pages 2819-2835.
Crossref
Paola Dongiovanni, Erika Paolini, Alberto Corsini, Cesare R. Sirtori & Massimiliano Ruscica. (2021) Nonalcoholic fatty liver disease or metabolic dysfunction‐associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. European Journal of Clinical Investigation 51:7.
Crossref
Stefania Sut, Irene Ferrarese, Maria Giovanna Lupo, Nicola De Zordi, Elisa Tripicchio, Nicola Ferri & Stefano Dall’ Acqua. (2021) The Modulation of PCSK9 and LDLR by Supercritical CO2 Extracts of Mentha longifolia and Isolated Piperitone Oxide, an In Vitro Study. Molecules 26:13, pages 3886.
Crossref
Yanan Guo, Binjie Yan, Shi Tai, Shenghua Zhou & Xi-Long Zheng. (2021) PCSK9: Associated with cardiac diseases and their risk factors?. Archives of Biochemistry and Biophysics 704, pages 108717.
Crossref
Jonathan Grimm, Georg Peschel, Martina Müller, Doris Schacherer, Reiner Wiest, Kilian Weigand & Christa Buechler. (2021) Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy. Journal of Clinical Medicine 10:8, pages 1621.
Crossref
Hitoshi Hamamura, Hisashi Adachi, Mika Enomoto, Ako Fukami, Sachiko Nakamura, Yume Nohara, Nagisa Morikawa, Akiko Sakaue, Kenta Toyomasu, Maki Yamamoto & Yoshihiro Fukumoto. (2021) Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population. Journal of Atherosclerosis and Thrombosis 28:4, pages 329-337.
Crossref
Roberto Scicali, Antonino Di Pino, Francesca Urbano, Viviana Ferrara, Simona Marchisello, Stefania Di Mauro, Alessandra Scamporrino, Agnese Filippello, Agata M. Rabuazzo, Francesco Purrello & Salvatore Piro. (2021) Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience. Nutrition, Metabolism and Cardiovascular Diseases 31:3, pages 869-879.
Crossref
Stefania Grimaudo, Stefano Bartesaghi, Raffaela Rametta, Fabio Marra, Rosellina Margherita Mancina, Jussi Pihlajamäki, Dorota Kakol‐Palm, Anne‐Christine Andréasson, Paola Dongiovanni, Anna Ludovica Fracanzani, Giulia Lori, Ville Männistö, Giovanni Pellegrini, Mohammad Bohlooly‐Y, Grazia Pennisi, Rosaria Maria Pipitone, Rocco Spagnuolo, Antonio Craxì, Daniel Lindén, Luca Valenti, Stefano Romeo & Salvatore Petta. (2020) PCSK9 rs11591147 R46L loss‐of‐function variant protects against liver damage in individuals with NAFLD . Liver International 41:2, pages 321-332.
Crossref
Stefania Cicolari, Chiara Pavanello, Elena Olmastroni, Marina Del Puppo, Marco Bertolotti, Giuliana Mombelli, Alberico L. Catapano, Laura Calabresi & Paolo Magni. (2021) Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (Bifidobacterium longum BB536, Red Yeast Rice Extract) (Randomized, Double-Blind, Placebo-Controlled Study). Nutrients 13:2, pages 427.
Crossref
Ga Eun Lee, Jinjoo Kim, Jihei Sara Lee, JaeSang Ko, Eun Jig Lee & Jin Sook Yoon. (2021) Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts. Frontiers in Endocrinology 11.
Crossref
Muhammad Shafiq, Timothy Walmann, Venkat Nutalapati, Cheryl Gibson & Yousaf Zafar. (2020) Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver. World Journal of Hepatology 12:12, pages 1258-1167.
Crossref
Jayanta Paul. (2020) Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult. Egyptian Liver Journal 10:1.
Crossref
Audrey Deprince, Joel T. Haas & Bart Staels. (2020) Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Molecular Metabolism 42, pages 101092.
Crossref
Maria R. Emma, Lydia Giannitrapani, Daniela Cabibi, Rossana Porcasi, Gianni Pantuso, Giuseppa Augello, Rosaria V. Giglio, Noemi Lo Re, Adele R. Capitano, Giuseppe Montalto, Maurizio Soresi & Melchiorre Cervello. (2020) Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1865:12, pages 158792.
Crossref
Maria G. Zenti, Maria G. Lupo, Sara De Martin, Anna Altomari, Serena Galvan, Marta Aventaggiato, Chiara Maneschi, Damiano Sandri, Elena Paiola, Marco Battistoni, Albino Eccher, Giovanni Targher, Enzo Bonora, Massimiliano Ruscica & Nicola Ferri. (2020) Impact of bariatric surgery-induced weight loss on circulating PCSK9 levels in obese patients. Nutrition, Metabolism and Cardiovascular Diseases 30:12, pages 2372-2378.
Crossref
Mi-Bo Kim, Yoojin Lee, Minkyung Bae, Hyunju Kang, Tho X. Pham, Siqi Hu, Ji-Young Lee & Young-Ki Park. (2020) Comprehensive characterization of metabolic, inflammatory and fibrotic changes in a mouse model of diet-derived nonalcoholic steatohepatitis. The Journal of Nutritional Biochemistry 85, pages 108463.
Crossref
Zhe Jiang, Takuya Hayashi, Kentaro Kashima, Kayo Kurotani, Bungo Shirouchi, Tetsuya Mizoue & Masao Sato. (2020) Alteration of Serum Phospholipid n‐6 Polyunsaturated Fatty Acid Compositions in Nonalcoholic Fatty Liver Disease in the Japanese Population: A Cross‐Sectional Study . Lipids 55:6, pages 599-614.
Crossref
Seon-Ok Lee, Yinzhu Xu, Hengmin Han, Seok-Tae Jeong, You-Kyung Lee, Jean Kyung Paik, Jin-Sol Cha & Hyo-Jeong Lee. (2020) Fermented Rhus Verniciflua Stokes Extract Alleviates Nonalcoholic Fatty Liver through the AMPK/SREBP1/PCSK9 Pathway in HFD-Induced Nonalcoholic Fatty Liver Animal Model. Applied Sciences 10:19, pages 6833.
Crossref
Silvano Fasolato, Sabrina Pigozzo, Patrizia Pontisso, Paolo Angeli, Massimiliano Ruscica, Edoardo Savarino, Sara De Martin, Maria Giovanna Lupo & Nicola Ferri. (2020) PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. Journal of Clinical Medicine 9:10, pages 3134.
Crossref
Marica Meroni, Miriam Longo & Paola Dongiovanni. (2020) Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. Exploration of Medicine 1:4, pages 218-243.
Crossref
Zheng Li, Cheng-Yin Ye, Li Wang, Jin-Mei Li & Lei Yang. (2020) Association of Genetic and Environmental Factors with Non-Alcoholic Fatty Liver Disease in a Chinese Han Population. International Journal of Environmental Research and Public Health 17:14, pages 5217.
Crossref
Paola Dongiovanni & Massimiliano Ruscica. (2019) Non-alcoholic fatty liver disease and cardiovascular disease: A still debated liaison. European Journal of Preventive Cardiology 27:10, pages 1056-1058.
Crossref
Arne Janssen, Diederick E Grobbee & Paul Dendale. (2019) Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease. European Journal of Preventive Cardiology 27:10, pages 1059-1063.
Crossref
Julita Anna Krahel, Anna Baran, Tomasz W. Kamiński & Iwona Flisiak. (2020) Proprotein Convertase Subtilisin/Kexin Type 9, Angiopoietin-Like Protein 8, Sortilin, and Cholesteryl Ester Transfer Protein—Friends of Foes for Psoriatic Patients at the Risk of Developing Cardiometabolic Syndrome?. International Journal of Molecular Sciences 21:10, pages 3682.
Crossref
Nadine Gehrke & Jörn M. Schattenberg. (2020) Metabolic Inflammation—A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?. Gastroenterology 158:7, pages 1929-1947.e6.
Crossref
Marica Meroni, Miriam Longo, Alice Rustichelli & Paola Dongiovanni. (2020) Nutrition and Genetics in NAFLD: The Perfect Binomium. International Journal of Molecular Sciences 21:8, pages 2986.
Crossref
Julita Anna Krahel, Anna Baran, Tomasz W. Kamiński, Magdalena Maciaszek & Iwona Flisiak. (2020) Methotrexate Decreases the Level of PCSK9—A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data. Journal of Clinical Medicine 9:4, pages 910.
Crossref
Martine Paquette, Dany Gauthier, Ann Chamberland, Annik Prat, Emanuella De Lucia Rolfe, Jon J. Rasmussen, Lydia Kaduka, Nabil G. Seidah, Sophie Bernard, Dirk L. Christensen & Alexis Baass. (2020) Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis. Clinical Biochemistry 77, pages 20-25.
Crossref
Thomas Marjot, Ahmad Moolla, Jeremy F Cobbold, Leanne Hodson & Jeremy W Tomlinson. (2020) Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocrine Reviews 41:1, pages 66-117.
Crossref
Jiang Du, Yu Ji, Liang Qiao, Yanli Liu & Juntang Lin. (2019) Cellular endo‐lysosomal dysfunction in the pathogenesis of non‐alcoholic fatty liver disease. Liver International 40:2, pages 271-280.
Crossref
Mohammed Eslam & Jacob George. (2019) Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nature Reviews Gastroenterology & Hepatology 17:1, pages 40-52.
Crossref
Marja-Riitta Taskinen, Elias Björnson, Linda Andersson, Juhani Kahri, Kimmo Porthan, Niina Matikainen, Sanni Söderlund, Kirsi Pietiläinen, Antti Hakkarainen, Nina Lundbom, Ralf Nilsson, Marcus Ståhlman, Martin Adiels, Paolo Parini, Chris Packard & Jan Borén. (2020) Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects. Journal of Clinical Lipidology 14:1, pages 77-87.
Crossref
Stéphane Ramin-Mangata, Matthieu Wargny, Matthieu Pichelin, Cédric Le May, Aurélie Thédrez, Valentin Blanchard, Brice Nativel, Raul D. Santos, Isabela M. Benseñor, Paulo A. Lotufo, Gilles Lambert & Bertrand Cariou. (2020) Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes. Atherosclerosis 293, pages 49-56.
Crossref
Massimiliano Ruscica, Chiara Pavanello, Sara Gandini, Chiara Macchi, Margherita Botta, Daria Dall’Orto, Marina Del Puppo, Marco Bertolotti, Raffaella Bosisio, Giuliana Mombelli, Cesare R. Sirtori, Laura Calabresi & Paolo Magni. (2019) Nutraceutical approach for the management of cardiovascular risk – a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study. Nutrition Journal 18:1.
Crossref
Chiara Caselli, Serena Del Turco, Rosetta Ragusa, Valentina Lorenzoni, Michiel De Graaf, Giuseppina Basta, Arthur Scholte, Raffaele De Caterina & Danilo Neglia. (2019) Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina. Cardiovascular Diabetology 18:1.
Crossref
Paul F. Lebeau, Jae Hyun Byun, Khrystyna Platko, Ali A. Al-Hashimi, Šárka Lhoták, Melissa E. MacDonald, Aurora Mejia-Benitez, Annik Prat, Suleiman A. Igdoura, Bernardo Trigatti, Kenneth N. Maclean, Nabil G. Seidah & Richard C. Austin. (2019) Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. JHEP Reports 1:6, pages 418-429.
Crossref
Ji Soo Lee, Partha Mukhopadhyay, Csaba Matyas, Eszter Trojnar, Janos Paloczi, Yuan Ru Yang, Brandon A. Blank, Cody Savage, Alexander V. Sorokin, Nehal N. Mehta, Janaina C. M. Vendruscolo, George F. Koob, Leandro F. Vendruscolo, Pal Pacher & Falk W. Lohoff. (2019) PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease. Scientific Reports 9:1.
Crossref
Grzegorczyk, Książek, Kurek, Łukaszuk, Rosołowski, Paszko, Krzyżak & Żendzian-Piotrowska. (2019) Effect of Sleeve Gastrectomy on Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Content and Lipid Metabolism in the Blood Plasma and Liver of Obese Wistar Rats. Nutrients 11:9, pages 2174.
Crossref
Yi Jing, Tianhui Hu, Chao Lin, Qingping Xiong, Fei Liu, Jun Yuan, Xiaojuan Zhao & Rong Wang. (2019) Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor α-mediated pathway in L02 cells. European Journal of Pharmacology 855, pages 216-226.
Crossref
C Macchi, M Banach, A Corsini, CR Sirtori, N Ferri & M Ruscica. (2019) Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents. European Journal of Preventive Cardiology 26:9, pages 930-949.
Crossref
Paul F. Lebeau, Jae Hyun Byun, Khrystyna Platko, Melissa E. MacDonald, Samantha V. Poon, Mahi Faiyaz, Nabil G. Seidah & Richard C. Austin. (2019) Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice. Journal of Biological Chemistry 294:23, pages 9037-9047.
Crossref
Jessica Mae Grindheim, Dario Nicetto, Greg Donahue & Kenneth S. Zaret. (2019) Polycomb Repressive Complex 2 Proteins EZH1 and EZH2 Regulate Timing of Postnatal Hepatocyte Maturation and Fibrosis by Repressing Genes With Euchromatic Promoters in Mice. Gastroenterology 156:6, pages 1834-1848.
Crossref
Baris Gencer, Sabrina Pagano, Nicolas Vuilleumier, Nathalie Satta, Cécile Delhumeau-Cartier, Christoph Meier, Sabine Bavamian, Fabrizio Montecucco, François Mach & Alexandra Calmy. (2019) Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naïve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort. Atherosclerosis 284, pages 253-259.
Crossref
Umair Iqbal, Brandon Perumpail, Daud Akhtar, Donghee Kim & Aijaz Ahmed. (2019) The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. Medicines 6:1, pages 41.
Crossref
Raul D. Santos, Luca Valenti & Stefano Romeo. (2019) Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis 282, pages 110-120.
Crossref
Tatsuki Ichikawa, Hisamitsu Miyaaki, Satoshi Miuma, Naota Taura, Yasuhide Motoyoshi, Hiroshi Akahoshi, Junpei Nakamura, Youichi Takahashi, Tetsurou Honda, Hiroyuki Yajima, Ryouhei Uehara, Naoyuki Hino, Syouhei Narita, Hisaya Tanaka, Seina Sasaki & Kazuhiko Nakao. (2019) Changes in serum LDL, PCSK9 and microRNA‑122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir. Biomedical Reports.
Crossref
Michael Kühl, Christian Binner, Joanna Jozwiak, Julia Fischer, Jochen Hahn, Alaeldin Addas, Boris Dinov, Jens Garbade, Gerhard Hindricks & Michael Borger. (2019) Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation. PLOS ONE 14:1, pages e0210373.
Crossref
Falk W Lohoff. (2018) Lipid-Lowering Drug Effects Beyond the Cardiovascular System: Relevance for Neuropsychiatric Disorders. International Journal of Neuropsychopharmacology 21:12, pages 1076-1078.
Crossref
Matthieu Wargny, Pierre-Henri Ducluzeau, Jean-Michel Petit, Cédric Le May, Sarra Smati, Lucie Arnaud, Matthieu Pichelin, Benjamin Bouillet, Adrien Lannes, Odile Blanchet, Philippe Lefebvre, Sven Francque, Luc Van Gaal, Bart Staels, Bruno Vergès, Jérôme Boursier & Bertrand Cariou. (2018) Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. Atherosclerosis 278, pages 82-90.
Crossref
Massimiliano Ruscica, Sara Simonelli, Margherita Botta, Alice Ossoli, Maria Giovanna Lupo, Paolo Magni, Alberto Corsini, Marcello Arca, Livia Pisciotta, Fabrizio Veglia, Guido Franceschini, Nicola Ferri & Laura Calabresi. (2018) Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1863:9, pages 991-997.
Crossref
Theodosios D. Filippatos, Eliza C. Christopoulou & Moses S. Elisaf. (2018) Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?. Current Opinion in Lipidology 29:4, pages 333-339.
Crossref
Yasunori Iida, Hiroki Tanaka, Hideto Sano, Yuko Suzuki, Hideyuki Shimizu & Tetsumei Urano. (2018) Ectopic Expression of PCSK9 by Smooth Muscle Cells Contributes to Aortic Dissection. Annals of Vascular Surgery 48, pages 195-203.
Crossref
Massimiliano Ruscica, Chiara Pavanello, Sara Gandini, Monica Gomaraschi, Cecilia Vitali, Chiara Macchi, Beatrice Morlotti, Gilda Aiello, Raffaella Bosisio, Laura Calabresi, Anna Arnoldi, Cesare R. Sirtori & Paolo Magni. (2016) Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial. European Journal of Nutrition 57:2, pages 499-511.
Crossref
Chiara Ricci, Massimiliano Ruscica, Marina Camera, Laura Rossetti, Chiara Macchi, Alessandra Colciago, Ilaria Zanotti, Maria Giovanna Lupo, Maria Pia Adorni, Arrigo F. G. Cicero, Federica Fogacci, Alberto Corsini & Nicola Ferri. (2018) PCSK9 induces a pro-inflammatory response in macrophages. Scientific Reports 8:1.
Crossref
Marjorie Boyer, Marie-Eve Piché, Audrey Auclair, Thomas Grenier-Larouche, Laurent Biertho, Simon Marceau, Frédéric-Simon Hould, Simon Biron, Stéfane Lebel, Odette Lescelleur, François Julien, Julie Martin, André Tchernof, André C Carpentier, Paul Poirier & Benoit J Arsenault. (2017) Acute and Chronic Impact of Bariatric Surgery on Plasma LDL Cholesterol and PCSK9 Levels in Patients With Severe Obesity. The Journal of Clinical Endocrinology & Metabolism 102:11, pages 4023-4030.
Crossref
Joseph M Pappachan, Shithu Babu, Babu Krishnan & Nishal C Ravindran. (2017) Non-alcoholic Fatty Liver Disease: A Clinical Update. Journal of Clinical and Translational Hepatology XX:XX, pages XX-XX.
Crossref
Sunjae Lee, Cheng Zhang, Zhengtao Liu, Martina Klevstig, Bani Mukhopadhyay, Mattias Bergentall, Resat Cinar, Marcus Ståhlman, Natasha Sikanic, Joshua K Park, Sumit Deshmukh, Azadeh M Harzandi, Tim Kuijpers, Morten Grøtli, Simon J Elsässer, Brian D Piening, Michael Snyder, Ulf Smith, Jens Nielsen, Fredrik Bäckhed, George Kunos, Mathias Uhlen, Jan Boren & Adil Mardinoglu. (2017) Network analyses identify liver‐specific targets for treating liver diseases. Molecular Systems Biology 13:8.
Crossref
Nicola Ferri, Silvia Marchianò, Maria Giovanna Lupo, Annalisa Trenti, Giuseppe Biondo, Paola Castaldello & Alberto Corsini. (2017) Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: Role of the small G protein Rac1. Pharmacological Research 122, pages 96-104.
Crossref
Vasilios G. Athyros, Theodore K. Alexandrides, Helen Bilianou, Evangelos Cholongitas, Michael Doumas, Emmanuel S. Ganotakis, John Goudevenos, Moses S. Elisaf, Georgios Germanidis, Olga Giouleme, Asterios Karagiannis, Charalambos Karvounis, Niki Katsiki, Vasilios Kotsis, Jannis Kountouras, Evangelos Liberopoulos, Christos Pitsavos, Stergios Polyzos, Loukianos S. Rallidis, Dimitrios Richter, Apostolos G. Tsapas, Alexandros D. Tselepis, Konstantinos Tsioufis, Konstantinos Tziomalos, Themistoklis Tzotzas, Themistoklis G. Vasiliadis, Charalambos Vlachopoulos, Dimitri P. Mikhailidis & Christos Mantzoros. (2017) The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 71, pages 17-32.
Crossref
Massimiliano Ruscica, Nicola Ferri, Federica Fogacci, Martina Rosticci, Margherita Botta, Silvia Marchiano, Paolo Magni, Sergio D'Addato, Marina Giovannini, Claudio Borghi, Arrigo F. G. Cicero, Martino Morbini, Enrico Bertagnin, Elisa Grandi, Silvia Palmesano, Elisabetta Rizzoli, Riccardo Urso, Giuseppe Derosa & Stefano Bacchelli. (2017) Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. Journal of the American Heart Association 6:5.
Crossref
Rainer Schulz & Klaus-Dieter Schlüter. (2017) PCSK9 targets important for lipid metabolism. Clinical Research in Cardiology Supplements 12:S1, pages 2-11.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.